Office: Cambridge, MA

Executive Assistant:
Sarah Parker
(617) 949-2176

Robert W. Liptak, MBA
Managing Director

Robert W. Liptak has been Managing Director of Clarus since the firm’s inception in 2005.  Prior to Clarus, Mr. Liptak was a General Partner at MPM Capital, a healthcare venture capital firm.  He has over 25 years of experience in the investment management industry focusing primarily on the establishment and management of various investment management businesses.

From 1995 to 2001, Mr. Liptak was a Partner with the Geometry Group, a diversified asset management firm focused on establishing investment management firms. From 1992 to 1995, Mr. Liptak was Vice President of Finance for Global Asset Management (USA) Inc., and began his career in 1986 with Price Waterhouse where he was a Manager in their Capital Market’s Group. Mr. Liptak is a Certified Public Accountant and received his MBA from Columbia University.  Mr. Liptak currently serves on the Board of Trustees at LaSalle University.  


Current Board Seats

Clarus Board Seats

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Type: Royalty Interest
Team: Robert W. Liptak
Scott Requadt
Nicholas J. Simon

Edev

Edev is a special purpose vehicle that has entered into an R&D project financing relationship with an undisclosed pharma company to finance multiple Phase 3 clinical trials for additional indications of an already-approved drug.

Fund: Clarus Lifesciences II, L.P.
Sector: Medical Device
Type: Private
Team: Robert W. Liptak
Kurt C. Wheeler
Emmett Cunningham

Flowonix Medical

Flowonix Medical is focused on developing better treatment options for the 75 million Americans in chronic pain, more than diabetes, heart disease, and cancer combined.  Our first product for delivery of intrathecal medication, the Prometra® programmable implantable pump, is undergoing clinical trials.  Flowonix is headquartered in Mount Olive, NJ.

Flowonix Website

Fund: Clarus Lifesciences I, L.P.
Sector: Medical Device
Type: Public
Team: Robert W. Liptak
Kurt C. Wheeler

Globus Medical, Inc. (NYSE:GMED)

Globus Medical, Inc. is focused on the development of products that enable spine surgeons to employ both fusion and non-fusion solutions to promote healing in patients with spinal disorders. Today Globus is one of the fastest growing spinal implant companies in the world and a recognized leader in the development of motion sparing technology.

Globus Website

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Type: Defined Exit
Team: Robert W. Liptak
Scott Requadt
Kurt C. Wheeler
Dennis Henner
Emmett Cunningham

SFJ Pharmaceuticals, Inc.

SFJ Pharmaceuticals® is a global specialty pharmaceutical company with an innovative pharmaceutical co-development model that provides an advantageous alternative to traditional pharma partnerships. SFJ Pharmaceuticals®’s unique partnering approach provides experienced clinical and medical professionals, clinical development resources and operational oversight and execution to accelerate late-phase drug development candidates across multiple indications and therapeutic areas. The result is pipeline acceleration for our partners. SFJ Pharmaceuticals® is staffed with a seasoned team of professionals with extensive experience in the global clinical development and regulatory approval of pharmaceutical products. SFJ Pharmaceuticals® has offices in the United States, Japan, Singapore, Korea, China, Spain and Germany.

SFJ Pharmaceuticals Website